In short
PF-07872437 is an investigational pneumococcal vaccine being studied in healthy infants, children, and adolescents. Two Phase 3 trials are currently authorised, together planning to enrol 3,600 participants. The trials assess the safety and immune response of the vaccine when given by intramuscular injection, compared with the authorised vaccine Prevenar 20.
PF-07872437 is an investigational vaccine being studied for protection against pneumococcal disease. It is given as a 0.5 ml intramuscular injection. In the two authorised Phase 3 trials, it is being compared with Prevenar 20, a 20-valent pneumococcal polysaccharide conjugate vaccine that is already authorised.
Key points
- PF-07872437 is an investigational pneumococcal vaccine given by intramuscular injection.
- Two Phase 3 trials are authorised, with planned enrolment of 2,400 and 1,200 participants.
- Both trials study pneumococcal immunisation in healthy infants, children, and adolescents.
- The main measures include local reactions, systemic events, and adverse events.
- The vaccine is being compared with Prevenar 20, an authorised pneumococcal conjugate vaccine.
What is PF-07872437?
PF-07872437 is an investigational pneumococcal vaccine. It is being developed as a new vaccine against pneumococcal disease, an infection caused by the bacterium Streptococcus pneumoniae. The vaccine is not yet authorised as a medicine; it is being studied in clinical trials.
How does PF-07872437 work?
The available trial records describe PF-07872437 as a pneumococcal vaccine, but do not give details of its mechanism of action. The comparison vaccine, Prevenar 20, is a pneumococcal polysaccharide conjugate vaccine that contains sugars from 20 types of pneumococcus linked to a carrier protein. This type of vaccine helps the immune system recognise and respond to the bacteria.
Which conditions is PF-07872437 studied for?
- Pneumococcal immunisation – both trials study the vaccine in healthy infants, children, and adolescents to see whether it can safely protect against pneumococcal disease.
How is PF-07872437 given?
PF-07872437 is given as a 0.5 ml intramuscular injection. The trial records list it as a drug product for intramuscular use.
What do the clinical trials show?
Two Phase 3 trials of PF-07872437 are authorised. Both are interventional studies in pneumococcal immunisation. Trial 2025-523447-35-02 plans to enrol 2,400 healthy infants and focuses on the safety of an expanded pneumococcal vaccine. Trial 2025-523445-10-00 plans to enrol 1,200 healthy children and adolescents and studies both safety and the immune response generated by the vaccine.
The trials measure prespecified local reactions such as redness, swelling, and pain at the injection site, as well as systemic events such as fever, decreased appetite, irritability, and drowsiness. They also record adverse events and serious adverse events. One trial additionally measures pneumococcal serotype-specific IgG concentrations and OPA titers, which show how strongly the immune system responds to the vaccine.
Both trials are currently authorised but not yet recruiting. They compare PF-07872437 with Prevenar 20, which is given in the same way.
What side effects are known?
The trial records do not report side effects from completed studies. The trials are designed to collect information on local reactions, systemic events, adverse events, and serious adverse events.